Loading
A phase 3 trial of Izalontamab brengitecan, Osimertinib in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) is a phase 3 interventional study registered as NCT06838273 by Sichuan Baili Pharmaceutical Co., Ltd., with 720 participants planned, started 2025-02-24 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1, Osimertinib, Osimertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, Small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Osimertinib, EGFR-mutated non-small-cell lung cancer.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.